Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsGeorge D. Demetri, Heikki Joensuu|New England Journal of Medicine|2002Cited by 4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upPaolo G. Casali, Martin Robinson, Sophie Piperno‐Neumann et al.|Annals of Oncology|2018Cited by 1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerHeikki Joensuu, Jorma Isola, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|New England Journal of Medicine|2006Cited by 1.4k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Stefan Michiels et al.|Annals of Oncology|2014Cited by 1.3k